

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period available?

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	56
1.2 Alpelisib (Piqray)	2
1.3 Elacestrant (Orserdu)	1
1.4 Fulvestrant (fulvestrant or Faslodex)	19
1.5 Inavolisib (Inaqovi)	0
1.6 Palbociclib (Ibrance)	18
1.7 Ribociclib (Kisqali)	48
1.8 Capivasertib (Truqap)	0
1.9 Talazoparib (Talzenna)	0
1.10 Olaparib (Lynparza)	2

Q2. How many patients received the following medicines for **early breast cancer** in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period for which data are available?

Name of combination or monotherapy	Number patients treated
2.1 Abemaciclib (Verzenios)	Data not readily available
2.2 Ribociclib (Kisqali)	0
2.3 Olaparib (Lynparza)	2

Q3. How many patients received the following medicines with **curative** treatment intent in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period for which data are available?

Name of combination or monotherapy	Number patients treated
3.1 Abemaciclib (Verzenios)	42
3.2 Ribociclib (Kisqali)	0

Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period available?

Name of combination or monotherapy	Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	3
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	5
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	11

Q5. How many patients were treated with Olaparib (Lynparza) for the following types of breast cancer in the 3 months between the start of Jan 2025 and the end of Mar 2025?

Type of breast cancer	Number patients treated
5.1 All types of breast cancer	1
5.2 Locally advanced or metastatic breast cancer	Data not readily available

Q6. How many patients were treated in total with the following products in the 3 months between 1<sup>st</sup> Jan 2025 to the end of Mar 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
6.1 Pertuzumab (Perjeta)	0
6.2 Pertuzumab with Trastuzumab (Phesgo)	36
6.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	21
6.4 Trastuzumab Deruxtecan (EnHertu)	3
6.5 Trastuzumab Emtansine (Kadcyla)	4
6.6 Tucatinib (Tukysa)	1
6.7 Neratinib (Nerlynx)	2

Q7. How many patients were treated with the following products for a diagnosis of Breast Cancer (*ICD-10 codes = C50\*, D509*) in the 3 months between 1<sup>st</sup> Jan 2025 to the end of Mar 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
7.1 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	21
7.2 Trastuzumab Deruxtecan (EnHertu)	3

Q8. How many patients received the following products with **curative treatment intent** in the 3 months between the start of Jan 2025 to the end of Mar 2025, or latest 3-month period for which data are available?

Treatment intent	Number patients treated
8.1 Pertuzumab (Perjeta)	Data not readily available
8.2 Pertuzumab with Trastuzumab (Phesgo)	Data not readily available
8.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, Trastuzumab)	Data not readily available
8.4 Trastuzumab Emtansine (Kadcyla)	Data not readily available

Q9. How many patients received the following products as part of **neoadjuvant** or **adjuvant** therapy in the 3 months between the start of Jan 2025 to the end of Mar 2025, or latest 3-month period for which data are available?

Treatment intent	Number patients treated
9.1 Pertuzumab (Perjeta)	Data not readily available
9.2 Pertuzumab with Trastuzumab (Phesgo)	Data not readily available
9.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	Data not readily available
9.4 Trastuzumab Emtansine (Kadcyla)	Data not readily available

Q10. How many patients received **trastuzumab deruxtecan (Enhertu)** for the following types of breast cancer in the 3 months between the start of Jan 2025 to the end of Mar 2025, or latest 3-month period for which data are available?

Treatment intent	Number patients treated
10.1 HER2+ <b>ve</b> Breast Cancer	Data not readily available
10.2 HER2- <b>low</b> Breast Cancer	Data not readily available

